A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care

NCT05195749 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Low Enrollment

Conditions

COVID-19

Interventions

DRUG: 101-PGC-005 ('005) + SOC
DRUG: Placebo + SOC

Sponsor

101 Therapeutics